| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Relmada Therapeutics (NASDAQ:RLMD) is set to give its latest quarterly earnings report on Wednesday, 2023-11-08. Here's what investors need to know before the announcement.
Analysts estimate that Relmada Therapeutics will report an earnings per share (EPS) of $-0.91.
Relmada Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Last quarter the company beat EPS by $0.06, which was followed by a 7.09% increase in the share price the next day.
Here's a look at Relmada Therapeutics's past performance and the resulting price change:
| Quarter | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.90 | -0.89 | -1.33 | -1.45 |
| EPS Actual | -0.84 | -0.87 | -1.28 | -1.31 |
| Price Change % | 7.09% | -6.31% | -2.16% | 8.73% |
Shares of Relmada Therapeutics were trading at $3.13 as of November 06. Over the last 52-week period, shares are down 45.16%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release.
To track all earnings releases for Relmada Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: RLMD
